

Salmeterol and Fluticasone: Understanding the combination inhaler for asthma and COPD

Sobiya shafi¹, J V Manisha vajra², Dr.A.V.Kishore Babu³, Dr.A.Srinivasa Rao⁴

Pharm D IV Year

BHASKAR PHARMACY COLLEGE, YENKAPALLY, MOINABAD.

Date of Submission: 01-01-2025

Date of Acceptance: 10-01-2025


ABSTRACT:

COPD and asthma are two crippling debilitating respiratory diseases affecting millions of patients worldwide, severely impairing their quality of life. Therefore, managing chronic lung diseases is a complex issue, which needs to control the inflammation and bronchoconstriction, two core mechanisms of both diseases. Combination therapy in one inhaler with Fluticasone Propionate and Salmeterol has emerged as the gold standard of preventing exacerbation, improved lung function and well-being for patients with COPD and asthma. It reduces airway inflammation through a long-acting bronchodilator salmeterol and corticosteroid fluticasone, which improves airflow. Such combination therapy has a better bronchodilation effect combined with anti-inflammatory action and the potential to control symptoms and prevent flare-ups and further improvements in lung function, all of which simplify treatment regimens and enhance patient adherence. Although generally well tolerated, careful monitoring for potential side effects, such as increased risk of pneumonia in COPD patients, is necessary. This combination is an important therapy in the management of chronic respiratory diseases.

I. INTRODUCTION:

Asthma, with chronic obstructive pulmonary disease commonly known as COPD, is a group of long-term respiratory conditions that are typically characterized by inflammation of the airways and subsequent constriction. This physiological process leads to a range of symptoms

that can have profound effects on a patient's quality of life, ranging from audible wheezing to frequent episodes of shortness of breath and a chronic cough that can be distressing. To manage these complex disorders effectively, it is necessary to approach the problem in a holistic way that not only addresses the underlying issue of inflammation but also the phenomenon of bronchoconstriction that affects the overall respiratory distress the patient experiences. One of the treatment modalities most frequently applied to patients diagnosed with moderate to severe asthma or Chronic Obstructive Pulmonary Disease (COPD) is combination inhalers. These are inhalers where various drugs are combined with their mechanism of action complementing one another to produce greater synergistic effects. The salmeterol and fluticasone given together in one inhaler act on the target sites with a two-pronged attack for the attainment of maximal effect. Salmeterol, being a LABA, is a bronchodilator that relaxes the airway's surrounding muscles, thereby improving the flow of air significantly. Fluticasone is a corticosteroid that reduces inflammation within the airways, hence preventing exacerbations and reducing symptoms in the long term. Adding these two drugs gives stronger therapeutic efficacy while providing an easy treatment program that has been enhanced to improve patients' adherence and quality of life. It has now become a very important management tool in asthma and COPD because it satisfies the needs of patients with the control of symptoms and a minimum reduction of exacerbation.



The two diseases differ mainly in cause, progression, and the nature of airway obstruction. COPD is a progressive lung disease most often caused by long-term exposure to harmful substances such as cigarette smoke or air pollution. Generally, it is diagnosed in patients over 40 years of age and causes permanent damage to the airways whose symptoms worsen with time. For instance, asthma diagnosis happens more often in young people and, generally speaking, is more frequently brought about by environmental causes of allergic conditions, cold, or physical exercise. It means that the reversible obstruction varies with asthma. The other major difference is that COPD is essentially chronic bronchitis and emphysema, both characterized by persistent airflow limitation; asthma is more about an inflammatory and narrowing of the airway that can be reversed by drugs like bronchodilators and corticosteroids. In addition, symptoms of COPD are more severe and chronic, whereas in asthma, symptoms are likely to be intermittent and less progressive. Lastly, the treatment strategies for COPD and asthma differ because asthma relies more on inhalers that produce rapid relief in acute symptoms, whereas COPD management involves the use of long-term medications, pulmonary rehabilitation, and oxygen therapy in advanced stages.

Though they differ in many ways, they do have some similarities like in both conditions, a direct consequence is the obstruction of the airways and breathing difficulties; such as wheezing, shortness of breath, and coughing. In the case of COPD and asthma, inflammation narrows and obstructs the airway, hinders airflow, and makes

breathing harder. Asthma is reversible inflammation due to allergens or irritants, whereas COPD causes chronic damage to the airways from smoking or pollutants. Both have the potential for exacerbations due to infections or allergens and are treated with similar drugs, including bronchodilators, to enhance airflow. Although their causes and progression differ, the symptoms and daily consequences of COPD and asthma are fairly similar, and both seriously impact quality of life and daily living.

Objective:

The objective revolves around Understanding the combination inhaler with salmeterol and fluticasone for asthma and COPD is aimed at recognizing its effectiveness in managing both symptoms and inflammation. Salmeterol is a long-acting beta-2 agonist (LABA) that provides prolonged bronchodilation, easing airway constriction, improving airflow, and reducing wheezing and breathlessness. It reduces the inflammation of the airway and therefore prevents the edema and mucous that cause exacerbations. With these, asthma and COPD control improves, exacerbations become less frequent and minor, and lung function along with quality of life will increase. This one-inhaler approach streamlines treatment, making it easier to adhere to and minimize the use of rescue drugs. Understanding this combination will optimize its use for the effective management of chronic respiratory conditions.

Methodology:

The methodology involves Understanding the Salmeterol and Fluticasone Combination Inhaler for Asthma and COPD.

1. Critically Review Evidence

Review clinical guidelines such as GINA for asthma and GOLD for COPD, and peer-reviewed studies on salmeterol with fluticasone combination inhaler.

Assess RCTs, meta-analyses, and real-world studies in terms of efficacy, safety, and outcomes.

2. Action Mechanism Study

Study the pharmacodynamics and pharmacokinetics of salmeterol: bronchodilation through activation of beta-2; and fluticasone: anti-inflammatory through corticosteroids.

Investigate how these medications work in concert to both alleviate symptoms and prevent exacerbations.

3. Consumer-Centric Data Gleaning

Collect patient-reported outcomes from users of the combination inhaler for asthma and COPD.

Assess lung function, including FEV1, symptoms, and quality of life with instruments such as the Asthma Control Test (ACT) or COPD Assessment Test (CAT).

4. Case Studies

Analyse case studies of asthma and COPD patients who received combination inhalers.

Identify patterns in disease control, exacerbation rates, and therapy response.

5. Comparative Analyses

Compare and contrast their efficacy and safety compared with LABA/ICS alternatives or triple therapy (LABA/ICS/LAMA).

6. Education & Training

Make materials accessible to the healthcare professionals and the patients for improving their knowledge about inhaler technique, dosing, and side effects.

Provide workshops or training sessions on the proper use of an inhaler.

7. Monitoring and Evaluation

Develop a monitoring system on treatment compliance, adverse effects, and outcomes.

Use spirometry, peak flow monitoring, and inflammation biomarkers such as FeNO for monitoring of effectiveness.

8. Feedback & Iterative Improvement:

Collect feedback from patients and providers on the effectiveness and usability of the inhaler. Develop on-campus education and practice efforts based on problems and success stories. This methodology ensures a holistic understanding of the salmeterol-fluticasone combination inhaler, promoting optimal use for managing asthma and COPD.

II. CONCLUSION:

In summary, the salmeterol and fluticasone inhaler are vital in the management of asthma and COPD as it regulates symptoms and inflammation. While salmeterol provides sustained bronchodilation, fluticasone suppresses airway inflammation and subsequently improves lung function and quality of life. The combination does simplify treatment, enhances compliance, and reduces the usage of rescue drugs. Understanding its mechanism of action, benefits, and use can optimize outcomes and control in chronic respiratory diseases over a long period. Monitoring regularly, with patient education, would help maximize the benefits and minimize risks.

REFERENCES:

- [1]. D'Urzo AD: Long-acting beta 2-agonists. Role in primary care asthma treatment. *Can Fam Physician*. 1997;43:1773-1777 [[PMC](#)] [[freearticle](#)] [[PubMed](#)] [[Google Scholar](#)]
- [2]. Derom EY, Pauwels RA, and van der Straeten ME: The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours. *J Allergy Clin Immunol*. 1992;89:811-815 [[PubMed](#)] [[Google Scholar](#)]
- [3]. Dransfield MT, and Bailey WC: Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease. *Expert Opin Pharmacother*. 2004;5:1815-1826 [[PubMed](#)] [[Google Scholar](#)]
- [4]. Johnson M: The anti-inflammatory profile of fluticasone propionate. *Allergy*. 1995;50(23 Suppl):11-14 [[PubMed](#)] [[Google Scholar](#)]

- [5]. Kirby S, Falcoz C, Daniel MJ, Milleri S, Squassante L, Ziviani L, and Ventresca GP: Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. *Eur J Clin Pharmacol.* 2001;56:781–791 [PubMed][Google Scholar]
- [6]. CHMP: Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD), Last updated: 1 August 2009. Available at:www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003504.pdf Accessed February22, 2018
- [7]. at:www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003504.pdf Accessed February22, 2018
- [8]. European Pharmacopoeia Monograph Preparations for Inhalation: Aerodynamic assessment of fine particles. Available at:<https://www.edgm.eu/en/europeanpharmacopoeia-ph-eur-9th-edition> Accessed February22, 2018
- [9]. Prescribing information of Advair Diskus: GlaxoSmithKline USA. Last updated February 2017. Available at:http://us.gsk.com/products/assets/us_advair.pdf Accessed February22, 2018
- [10]. Jögi R, Julge K, Samarüütel P, Raatikainen L, and Vanto T: Peak inspiratory flow rates through placebo dry powder inhaler device in various asthma and COPD patients. *Eur Respir J.* 2012;40(Suppl 56):P3438 [Google Scholar]
- [11]. Helgersson E, and Zhang Z: Analytical method for the determination of fluticasone propionate and salmeterol in potassium oxalate/sodium fluoride human plasma by UPLC-MS/MS. *PPD Method.* P988.01, May 2010 [Google Scholar]
- [12]. Hochberg Y: A sharper Bonferroni procedure for multiple tests of significance. *Biometrika.* 1988;75:800–802 [Google Scholar]
- [13]. Zheng C, Wang J, and Zhao L: Testing bioequivalence for multiple formulations with power and sample size calculations. *Pharm Stat.* 2012;11:334–341 [PubMed][Google Scholar]
- [14]. European public assessment report (EPAR) for DuoResp Spiromax 2014. Available at:www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/002348/WC500167183.pdf Accessed February22, 2018
- [15]. Public assessment report for Airflusal Forspiro 2014. Available at:<https://docetp.mpa.se/LMF/Airflusal%20Forspiro,%20inhalation%20powder,%20pre-dispensed%20ENG%20PAR.pdf> Accessed February22, 2018
- [16]. European public assessment report (EPAR) for Aerivio Spiromax 2016. Available at:www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/002752/WC500212331.pdf Accessed February22, 2018
- [17].
- [18].
- [19].